From: Pierre Lebreton [redacted]

Sent: [redacted], 2005 [redacted]

To: [redacted]

Subject: info puragen

Mentor's Puragen and Puragen Plus Dermal Filler Products Approved in Canada Monday December 19, 8:30 am ET Non-Animal-Based, Stabilized, Hyaluronic Acid Dermal Filler Products Manufactured with Mentor's Patented DXL(TM) Technology

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Dec. 19, 2005--Mentor Corporation (NYSE:MNT - News), a leading supplier of medical products in the United States and internationally, today announced that it has received approval to begin marketing and distributing its Puragen(TM) and Puragen Plus(TM) hyaluronic acid-based dermal filler products in Canada. Both products are indicated for the correction of facial folds and wrinkles and for lip augmentation and will be distributed through Mentor's Canadian subsidiary.
ADVERTISEMENT

"Mentor's dermal filler products are important new options that help me optimize facial rejuvenation outcomes for my patients," commented Claudio De Lorenzi, M.D., Board Certified Plastic Surgeon and past-President of the Canadian Society for Aesthetic Plastic Surgery and current President of the Canadian Laser Aesthetic Surgery Society. "I am pleased to now have access to both of these products for my patients in Canada. It is important to have alternatives, and I predict that a product that contains anesthetic will be extremely popular among doctors and patients."

The medical device license applications granted by Health Canada for Puragen and Puragen Plus were based on data from the Company's U.S. pivotal clinical trial for Puragen Plus. Both Puragen and Puragen Plus are uniquely stabilized through Mentor's patent-protected DXL(TM) technology, which introduces two discrete cross-linking reactions to provide improved product stability relative to all other commercially available hyaluronic acid based dermal fillers on the market in Europe, Canada and the United States. Puragen Plus is the only hyaluronic acid-based product on the market in Canada that is formulated with an anesthetic for improved patient comfort.

"Puragen and Puragen Plus are Mentor's first products for the fast growing facial rejuvenation market, and we are pleased that they are now available in Canada," commented Joshua H. Levine, President and Chief Executive Officer of Mentor Corporation. "We are committed to developing and marketing leading products based on advancements in science and technology and expect to expand our portfolio with botulinum toxin and other products used in non-surgical cosmetic procedures in the future."

Puragen was launched in Europe in May 2005. The CE Mark for Puragen Plus is pending. In the United States, Mentor expects to complete the filing of its pre-market approval application for Puragen Plus in the fourth quarter of fiscal year 2006, which ends March 31, 2006.

About Mentor Corporation

Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global healthcare market. The Company develops, manufactures and markets innovative, science-based products for the aesthetics, urologic specialties and clinical and consumer healthcare markets around the world. The Company's website is www.mentorcorp.com.

Safe Harbor Statement

All statements included or incorporated by reference in this release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by us. Forward-looking statements in this press release include but are not limited to those statements related to the "fast growing facial rejuvenation market", "our commitment to developing and marketing leading products based on advancements in science and technology", and "expect to expand our portfolio with botulinum toxin and other products used in non-surgical cosmetic procedures in the future." Forward-looking statements can also be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "provide," "potential," "continue," similar expressions, and variations or negatives of these words. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements speak only as of the date hereof and are based upon the information available to us at this time. Such information is subject to change, and we will not necessarily inform you of such changes. These statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statement as a result of various factors.

The Securities and Exchange Commission filings of Mentor, including, without limitation, its Annual Reports on Form 10-K, subsequent quarterly reports on Form 10-Q, and recent Current Reports on Form 8-K, discuss important risk factors that could contribute to such differences or otherwise affect its business, results of operations and financial condition. Mentor undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Contact:
Mentor Corporation
Peter R. Nicholson, 805-879-6082

From: Pierre Lebreton [redacted]

Sent: [redacted], 2006 [redacted]

To: [redacted]

Subject: TR: Keyword News: [hyaluronic]

pour infos, nouveau HA filler avec lidocaine (REDEFYNE) -----Message d'origine----- [redacted]

Yahoo! Alerts Yahoo! News - My Alerts - Edit Alert
Friday, February 17, 2006 11:05 AM PST

Anika gets EU OK to sell wrinkle filler
Mass High Tech Fri, 17 Feb 2006 7:43 AM PST
The European Union has given Woburn-based Anika Therapeutics Inc. CE Mark approval to market its cosmetic tissue augmentation product, Redefyne, in the EU.

Anika Therapeutics Receives CE Mark for its REDEFYNE(TM) Cosmetic Tissue Augmentation Product
PR Newswire via Yahoo! Finance Thu, 16 Feb 2006 1:45 PM PST
Anika Therapeutics, Inc. today announced that it has received CE Mark approval to market its cosmetic tissue augmentation product, REDEFYNE, in the European Union. REDEFYNE is an injectable soft tissue filler for facial wrinkles, scar remediation and lip augmentation.

See more news stories that match my keyword

To: Lebreton_[redacted]
Cc: [redacted]
From: [redacted]
Sent: [redacted] 2008 [redacted]
Importance: Normal
MAIL_RECEIVED: [redacted] 2008 [redacted]
BUSINESS WIRE_07.08.08_Anika Therapeutics Announces.doc

Pierre/[redacted]

[redacted]

About Elevess Anika's Elevess is the first FDA approved injectable soft-tissue filler to combine hyaluronic acid (HA) and lidocaine, a local anesthetic that improves patient comfort, and provides physicians with a new alternative for their aesthetic practice.

[redacted]

[redacted]

[redacted]

[redacted]

Allergan Inc.

2525 Dupont Drive

Irvine, CA 92612

[redacted]

[redacted]@allergan.com

BUSINESS WIRE

Anika Therapeutics Announces Exclusive U.S. Distribution Agreement For Elevess Injectable Dermal Filler ; Anika's HA-Based Dermal Filler Incorporating Lidocaine To Be Distributed By Artes Medical
July 8, 2008

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has signed an exclusive agreement with **Artes Medical**, Inc., a medical **aesthetics** company, to distribute and market **ELEVESS**™, Anika's cross-linked hyaluronic acid-based (HA) injectable dermal filler. **ELEVESS** is an injectable filler that reduces the appearance of facial wrinkles and folds such as nasolabial folds, and is the first HA-based dermal filler approved by the Food and Drug Administration ("FDA") to incorporate the anesthetic lidocaine to improve patient comfort. **Artes Medical** manufactures, markets and sells **ArteFill**(®), the first and only FDA-approved, nonresorbable dermal filler for the correction of smile lines.

"We are very pleased to reach this agreement with **Artes Medical** to distribute **ELEVESS**, our breakthrough dermal filler product," said Anika President and Chief Executive Officer Charles H. Sherwood, Ph.D. "After undertaking an extensive search with a number of potential commercialization partners, we believe that **Artes Medical** possesses the capabilities that can help **ELEVESS** achieve its full potential in the marketplace. Artes' highly experienced sales force has well established relationships with the leading aesthetic physicians in markets throughout the United States. In addition, their complementary product, deep understanding of the injectable dermal filler marketplace and compatible culture make this a highly synergistic agreement for both companies." Under the terms of the agreement, **Artes Medical** will receive exclusive distribution and marketing rights for **ELEVESS** in the United States.

"Going forward, we are actively seeking partners with characteristics and capabilities similar to **Artes Medical** to help us distribute **ELEVESS** in Europe, Canada, and the rest of the world," said Sherwood. "Our hopes are high for this product and we are eager for an increasing number of doctors and patients to experience its benefits."

About **ELEVESS**:

Anika's **ELEVESS** is the first FDA approved injectable dermal filler to combine hyaluronic acid (HA) and lidocaine, a local anesthetic that improves patient comfort, and provides physicians with a new alternative for their aesthetic practice. Hyaluronic acid is a naturally occurring polymer found throughout the body and is present in the **skin**, where it supports **skin** structure and elasticity. Designed for longer durability based on its proprietary cross-linking technology and its high concentration of Anika's chemically modified hyaluronic acid, **ELEVESS** has been approved for sale in the United States, the European Union and Canada.

About **Anika Therapeutics**, Inc.

Headquartered in Bedford, Mass., **Anika Therapeutics**, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products include ORTHOVISC(®), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the **ELEVESS**™ family of aesthetic **dermatology** products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™-II and Shellgel™ injectable viscoelastic HA products for ophthalmic surgery; INCERT(®), an HA-based anti-adhesive for surgical applications; ORTHOVISC(®) Mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC™ a single-injection osteoarthritis product based on its proprietary cross-linking technology and available in Europe; and next generation products for joint health and aesthetic **dermatology** based on the Company's proprietary, chemically modified HA.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.